This site and its domain are for sale. Email the owner if you want to talk about it.

bioclocktest.com

Do Ageing Clocks Predict Disease and Death?

Clocks predict death for crowds, modestly, in blood. For one person, the only test validated against death is still death.

A vial of blood and a cotton swab laid side by side on a plain laboratory bench beside a stack of paper charts.

Researchers have spent years taking blood from people, reading chemical tags off their DNA, and then waiting to see who dies. It mostly works, in the narrow way it was designed to. In blood-based studies, the epigenetic clock mortality evidence shows that clocks like GrimAge are associated with higher risk of death and disease, sometimes even after the researchers account for other things they already knew about the participants. The effects are real. In the most carefully adjusted study here, they are also small.

What the evidence does not show is that a clock can substitute for actually waiting, that moving your clock moves your odds, or that a cheek swab means what a blood draw means. A 2026 systematic review of intervention trials found no validated case of the first. The easiest way to see why is to build the idea up one reasonable step at a time, until it stops being reasonable.

What a clock that only guesses your age is good for

Step one is modest. You take DNA methylation (the chemistry has its own article on this site) and fit a model that guesses how old someone is. The Horvath pan-tissue clock does this with 353 CpG loci and lands within about 3.6 years on average across many tissue types. The Hannum clock, built from the whole blood of 482 people, uses 71.

This is an elaborate machine for producing a number already printed on your driver’s license.

Nobody wants it for that, presumably. The interesting part is the miss. If the clock says 58 and the license says 50, maybe the extra eight years mean something, and maybe the body is running ahead of the calendar. That is the premise of the whole field, and it is a sensible premise.

The trouble is that a clock graded only on hitting the calendar treats those eight years as an error it would rather not have made. CD Genomics describes first-generation clocks as “better at capturing normal aging than pathological aging related to disease and mortality risk.” They were built to be right about your birthday. Being right about your death was never on the rubric.

What happens when you train the clock on death

Step two: change the rubric. Second-generation clocks, PhenoAge and GrimAge, swapped the training target from chronological age to clinical phenotypes, disease incidence and all-cause mortality (GrimAge is the one literally trained on death, and it gets its own article here).

So now the clock predicts death. Well, no. It predicts death in the data it was fitted on, which is in some sense just the exam it already saw. GrimAge’s relationship with its training cohort is, professionally speaking, blurry: they were introduced early, spent a lot of late nights alone with the same spreadsheet, and now each one finishes the other’s sentences. The stranger and more precise version is that a mortality clock, on the day it is born, is a very elaborate summary of deaths that have already happened.

The only question worth asking is whether it works on deaths that haven’t happened yet. That is prospective validation, and it mostly consists of patience. You measure living people and write down what the clock says. Then you wait.

What the epigenetic clock mortality numbers say

Step three is the waiting. The PhenoAge validation in NHANES IV had mortality follow-up spanning 12.6 years, using National Death Index records through December 31, 2011. (I find it hard to wait for a large PDF to finish loading, which is part of why I write about cohort studies instead of running them.)

The result usually comes out as a hazard ratio. A hazard ratio of 1.40 means that at any moment during follow-up, one group is dying at 1.4 times the rate of the comparison group. When it is stated “per standard deviation,” it means each step of ordinary spread in the clock reading multiplies the rate by that amount.

In the Head and Neck 5000 cohort, made up of people already diagnosed with oropharyngeal cancer, accelerated GrimAge came with a hazard ratio for all-cause mortality of 1.40 per standard deviation, with a 95% confidence interval of 1.06 to 1.83. Accelerated Hannum age came in at 1.30 (1.07 to 1.57). The confidence interval is the range the study can’t rule out, and for GrimAge it runs from a 6% bump to an 83% bump. That is a range you could park a bus in.

It isn’t only methylation. Deep-learning clocks built from routine blood markers in NHANES produced mortality hazard ratios of 1.059 and 1.039 for their accelerated-aging measures, and were linked to deaths from cardiovascular and cerebrovascular disease and cancer. A proteomic clock built in the UK Biobank from 2,923 proteins in 53,021 people showed stronger age-adjusted associations with mortality and 18 diseases than PhenoAge, BioAge or telomere length. Everybody’s clock predicts death a little. The competition is over the margins.

Whether the clock beats the usual risk factors

Step four is the one medicine actually cares about. Doctors already have standard risk factors (the stuff a checkup already measures), and a new test is useful only if it adds something those don’t. Statisticians check this by adjusting: they put the known factors into the model alongside the clock and see what is left.

In the MESA study’s fully adjusted models, GrimAge was still independently associated with higher risk of composite cardiovascular disease, with a hazard ratio of 1.05 (1.02 to 1.08). The interval stays above 1, so it isn’t nothing. It is 5%.

Five percent.

Look, there are two ways to read that, and the facts here don’t pick one. In the first, after you remove everything clinicians already measure, there is still something in the methylation that knows about the heart, which is strange and interesting. In the second, the clock mostly re-measures what the doctor already had, and 1.05 is the crumbs left over once the doctor’s numbers have eaten. Both readings fit the same number.

Other studies point in the same direction without settling it. In men with hypertension, ischemic heart disease, obesity or dyslipidemia, only GrimAge and DunedinPACE picked up the disease signal; none of 19 first-generation clocks did. A commentary in the AMA Journal of Ethics calls epigenetic clock tests “fairly reliable indicators” of risk for certain age-related diseases, in the same piece that calls biological age a fiction. I feel like both of those can be true.

Why a clock can’t yet stand in for the outcome

Step five is where the road gets steep. Following people for 12.6 years is slow and expensive. It would be much nicer to run a short trial, see whether a treatment lowers the clock, and call that a win. Medicine uses surrogate endpoints like this all the time, once the surrogate has earned it.

Here is an invented version, pushed to the end. A company runs a trial, and its pill lowers DunedinPACE (which the Moffitt and Caspi lab describes as the clock most sensitive to intervention). A sponsor tells the investor call, “Hey guys, the cohort got 0.3 years younger this quarter.” A rival pill lowers it more. An insurer prices premiums off the clock. A dating app lists it next to height. At no point does anyone check whether fewer people died, because checking would take 12.6 years, and the whole point was not to.

The real world has not gotten there, and the reason is boring. A 2026 systematic review of 26 geroscience intervention studies found that changes in clocks and changes in clinical outcomes lined up inconsistently, and rated the certainty of evidence “very low” across every body of evidence it assessed. It identified no trial-level surrogate validation, and concluded that clocks should be treated as exploratory or adjunctive biomarkers. Moving the clock has not been shown to move the thing it predicts.

How far down this road the real world has gotten

Steps one through four are done, in blood, at the level of large groups. The Scientist notes that the link to disease and mortality “has not been established for saliva-based clocks,” and that a blood-trained clock applied to saliva without correction can produce substantial errors. As of 2026 the field has no reference standards, so one sample sent to different validated labs need not come back with the same age.

Then there is stability. Nearly all of 18 clocks tested on the TranslAGE platform reproduced well on replicate assays, but reliability across samples taken hours apart, before and after meals or under stress was markedly lower for most, and technical robustness did not predict biological reliability. Elysium Health, on a page explaining the science behind its Index product, reports that technical replicates of Horvath, Hannum and PhenoAge deviated by three to nine years. It is a bathroom scale that agrees with itself twice in a row and then disagrees after lunch.

None of this is dumb. A hazard ratio of 1.05 survives that kind of noise because it is averaged over thousands of people, and I assume that is exactly why the cohort studies work. A single reading for a single person gets averaged over nobody.

So the clocks do predict death, for crowds. For one person, the only test fully validated against death is still death.

Sources

  1. Epigenetic Clocks Power Biological Age Data, But Why Do Results Differ Across Tests? | The Scientist
  2. Choosing Epigenetic Clock Models: Horvath, Hannum, PhenoAge, GrimAge and Beyond - CD Genomics
  3. What Are the Most Ethically Salient Implications of Epigenetic Age Testing? – Dec 2025 | Journal of Ethics | American Medical Association
  4. Biological versus Technical Reliability of Epigenetic Clocks and Implications for Disease Prognosis and Intervention Response
  5. Epigenetic Aging Clocks and Incident Cardiovascular Outcomes: Results From the MESA
  6. Epigenetic biomarkers of ageing are predictive of mortality risk in a longitudinal clinical cohort of individuals diagnosed with oropharyngeal cancer
  7. Concordance between changes in epigenetic clocks and changes in clinical outcomes in geroscience intervention trials: A systematic review
  8. Frontiers | Development and validation of deep learning- and ensemble learning-based biological ages in the NHANES study
  9. A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study | PLOS Medicine
  10. Four Aspects to Interpret Epigenetic Clock Results - CD Genomics
  11. Biological versus Technical Reliability of Epigenetic Clocks and Implications for Disease Prognosis and Intervention Response
  12. The Science Behind Index | Elysium Health
  13. Epigenetic signatures of cardiometabolic risk in men: accelerated aging and differential methylation replicated across cohorts
  14. DunedinPACE | Moffitt & Caspi: Genes, Environment, Health, Behavior
  15. Epigenetic Clock | UCSF SMN
  16. Proteomic aging clock (PAC) predicts age-related outcomes in middle-aged and older adults

Bio Clock Test explains published research. It is not medical advice and it does not diagnose anything. We never recommend a test, a supplement or a treatment. Talk to a clinician about your health.

Read next